TORONTO, May 02, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (“FDA”) for KETARX (ketamine) for the treatment for levodopa-induced dyskinesia in Parkinson’s disease (“LID-PD”).


Previous articlePT408 – Fireside Project: Harm Reduction Through Free Peer Support
Next articlePsychedelics, The Brain, and the Future of Mental Health